Want to see IN:HIKAL full AI Analyst Report?
HIKAL Stock Chart & Stats
₹217.20
₹4.58(2.11%)
At close: 4:00 PM EDT
₹217.20
₹4.58(2.11%)
Day’s Range― - ―
52-Week Range₹145.95 - ₹260.80
Previous CloseN/A
Volume197.35K
Average Volume (3M)130.57K
Market Cap
₹26.20B
Enterprise Value₹24.83B
Total Cash (Recent Filing)₹138.00M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)-2.74
Shares Outstanding123,300,750
10 Day Avg. Volume37,537
30 Day Avg. Volume130,572
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.51
Price to Sales (P/S)1.06
P/FCF Ratio20.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.9
Revenue Forecast (FY)₹19.00B
Bulls Say, Bears Say
Bulls Say
Cash GenerationPositive operating cash flow and free cash flow in 2026 indicate that Hikal continues converting business activity into cash despite its loss-making year. This supports ongoing operations and provides some internal funding capacity for investment, debt service, and customer-related manufacturing needs.
Improving LeverageDebt reduction alongside a sizable equity base improves Hikal’s balance-sheet flexibility and lowers the immediate burden of leverage. This gives the company greater capacity to manage operating volatility and preserve funding options while profitability remains under pressure.
Specialty Manufacturing ModelHikal’s custom manufacturing and process-development model positions it as an embedded supplier in pharmaceutical and agrochemical value chains. Approved-supplier relationships and repeat orders for validated molecules can support recurring business and deepen customer integration over time.
Bears Say
Profitability DeteriorationThe shift from historical profitability to a net loss materially weakens earnings quality and reduces confidence in near-term returns from the existing business. Unless margins recover or operating costs ease, sustained losses could constrain reinvestment and weaken financial flexibility.
Uneven Revenue MomentumInconsistent revenue performance suggests that demand across Hikal’s pharmaceutical and agrochemical activities has not yet established a dependable growth trajectory. Continued weak top-line momentum would limit operating leverage and make recovery in profitability more difficult to sustain.
Volatile Free Cash FlowAlthough free cash flow remained positive in 2026, its material decline and prior negative year show that cash conversion can vary significantly. This volatility may reduce the reliability of internally generated funds for expansion, capital spending, and balance-sheet strengthening.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹145.95 and its highest was ₹260.80 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹26.20B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Nov 18, 2026 which is in 35 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on Aug 06, 2026. The company reported -₹1.3 earnings per share for the quarter.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.4 which represents an annual dividend yield of 0.28%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of -₹1.3 in its last earnings report. Following the earnings report the stock price went down -4.222%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Rossari Biotech Ltd
―
Solara Active Pharma Sciences Ltd.
―
Supriya Lifescience Limited
―
Wockhardt Limited
―